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Abstract
Anemia is a common manifestation of inflammatory bowel disease (IBD), but it remains
unclear whether anemia is associated with the development of IBD. We assessed the risk of
developing IBD in anemic patients, and stratified the results with respect to their hemoglobin
concentrations. A population-based study was conducted using the National Healthcare
Insurance Service database in South Korea. We included individuals over 20 years’ old who
participated in the national health screening program in 2009 (n = 9,962,064). Anemia was
defined as a hemoglobin level less than 13 g/dL in men and less than 12 g/dL in women. We
compared the rate of newly diagnosed IBD in anemic patients and non-anemic individuals.
Newly diagnosed IBD was identified using both the ICD-10 medical code and specialized V
codes for rare intractable diseases in South Korea. During the mean follow-up period of 7.3
years, the incidences of CD and UC in anemic patients were 2.89 and 6.88 per 100,000 per-
son-years, respectively. The risk of CD was significantly higher in anemic patients than in
non-anemic individuals [adjusted hazard ratio (aHR), 2.084; 95% confidence interval (CI),
1.769–2.455]. The risk of CD development was inversely proportional to the hemoglobin
concentration. A J-curve relationship was observed between age and the risk of CD in ane-
mic patients. The risk of CD in male anemic patients was significantly higher than that in
female anemic patients (aHR, 1.432 vs. 1.240, respectively). By contrast, there was no sta-
tistically significant difference in the risk of developing UC in anemic and non-anemic individ-
uals (aHR, 0.972; 95% CI, 0.880–1.073). This work indicates that anemia is related to the
development of CD, and this risk was inversely proportional to the hemoglobin
concentration.
PLOS ONE







Citation: Kang EA, Chun J, Im JP, Lee HJ, Han K,
Soh H, et al. (2020) Anemia is associated with the
risk of Crohn’s disease, not ulcerative colitis: A
nationwide population-based cohort study. PLoS
ONE 15(9): e0238244. https://doi.org/10.1371/
journal.pone.0238244
Editor: Pal Bela Szecsi, Copenhagen University
Hospital Holbæk, DENMARK
Received: February 14, 2020
Accepted: August 12, 2020
Published: September 8, 2020
Copyright: © 2020 Kang et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Original data cannot
be shared publicly because of the PERSONAL
INFORMATION PROTECTION ACT in South Korea.
You can request a minimum data set from the
National Health Insurance Data Sharing Service
website (https://nhiss.nhis.or.kr/).
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
Introduction
Anemia is defined as a hemoglobin concentration less than 13 g/dL in men and less than 12 g/
dL in women according to World Health Organization (WHO) standards [1]. Anemia can be
caused by a variety of etiologies such as iron deficiency, chronic diseases, vitamin B12 or folate
deficiency, and genetic factors. Anemia is a known risk factor for cardiovascular diseases,
dementia, and chronic medical illness, leading to an increase in all-cause mortality [2–5].
Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis
(UC). IBD is a chronic inflammatory gastrointestinal disorder that involves complex interac-
tions among genetic, environmental, immunological, and microbiological factors. The inci-
dence of IBD in South Korea has been increasing, which causes higher medical and
socioeconomic burdens [6]. IBD patients experience various systemic manifestations related
to intestinal inflammation during disease progression. Anemia is a prevalent extraintestinal
manifestation of IBD, especially for patients with CD. Malabsorption, malnutrition, and
micronutrient deficiency cause anemia in patients with IBD. Gastrointestinal bleeding also
can induce or aggravate anemia [7, 8].
It is important to find a surrogate marker for early detection of IBD to prevent complica-
tions and surgery and improve the quality of life for those with IBD. Colonoscopy is the most
effective diagnostic test to evaluate the presence of colitis in asymptomatic individuals, but this
test is not appropriate for disease screening due to its expense and invasiveness. The fecal cal-
protectin is a useful surrogate marker for predicting clinical recurrence of IBD [9]. However, it
remains to be determined whether fecal calprotectin can be used as a screening tool for the
early detection of IBD [10, 11]. Anemia may be a promising surrogate marker for early detec-
tion of IBD, but it remains to be determined whether anemia can be a marker for the detection
of subclinical IBD. Recently, we reported that anemia was significantly associated with an
increased risk of CD over the age of 40 [12]. However, the impacts of anemia on the occur-
rence of CD based on the severity of anemia and various subgroups have not been fully evalu-
ated yet. The aim of this study was to investigate the incidence and risk of IBD based on the
presence and severity of anemia.
Materials and methods
Study design
This was a nationwide population-based cohort study using the National Health Insurance
(NHI) database in South Korea. The NHI is a public health insurance that is mandatory for
97% of the Korean population, except for those with the lowest incomes who are supported by
Medical aid. The National Health Screening Program (NHSP) is recommended every two
years for adults over 20 years old. The NHI and NHSP database includes demographic data
such as age, sex, residence, smoking, alcohol consumption, height, body weight, laboratory
results, medical diagnoses based on the International Classification of Disease 10th revision
(ICD-10) codes, and drug prescriptions. As the burden of medical expenses for rare and incur-
able diseases has been steadily increasing, a specialized V code was developed in Korea for rare
and intractable disease (RID) such as IBD. Physicians can register the V codes according to the
diagnostic criteria for each RID.
Study population
We included individuals over 20 years old who participated in the NHSP from 1st of January
2009 to 31st of December 2009, the index year. Patients diagnosed with IBD from 1st of January
2002 to the index date were excluded from this study (washout period). Individuals who were
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diagnosed with IBD for the first year since 2009 were excluded to eliminate the possibility of
IBD unrelated to anemia (lag period). We compared individuals with anemia to those who did
not have anemia. The included population was followed until December 31, 2016.
Definition and covariates
IBD was detected using both the ICD-10 codes (K50 for CD and K51 for UC) and the V codes
for RIDs (V130 for CD and V131 for UC). The operational definition of IBD was validated as
described previously [13–15], with a sensitivity of 94.5% for CD and 96.4% for UC. Anemia
was defined based on WHO criteria as a hemoglobin level less than 13 g/dL for men and less
than 12 g/dL for women. Anemia during follow-up was defined as the presence of anemia at a
2-year follow-up exam in 2011 but without anemia at baseline, 2009. The study participants
were classified as current or former smokers or nonsmokers based on self-reporting. Current
smokers were defined as persons who continued to smoke at least a total of 100 cigarettes life-
long, and former smokers were defined as those who had smoked more than a total of 100 cig-
arettes but quit smoking at least one month before enrollment. Nonsmokers were defined as
those who had smoked less than 100 cigarettes. Alcohol consumption was categorized as non-
drinkers, mild drinkers (alcohol consumption < 30 g/day), and heavy drinkers (alcohol
consumption� 30 g/day). BMI (kg/m2) was classified as follows: < 18.5 for underweight,
18.5–22.9 for normal-weight, 23.0–24.9 for overweight (pre-obese), and� 25.0 for obese [16].
Physical activity was classified based on the intensity and frequency of exercise as follows:
none, less than 2 times per week, and 2 times or more per week for at least 20 minutes [17].
Hypertension was defined as systolic/diastolic blood pressure� 140/90 mmHg, or a combina-
tion of ICD-10 codes (I10–13, I15) and prescription for anti-hypertensive medications. Dysli-
pidemia was identified as an ICD-10 code (E78) and medications for dyslipidemia, or a fasting
total serum cholesterol level of� 240 mg/dL. Diabetes mellitus (DM) was identified using
ICD-10 codes (E11–14) and anti-diabetic medications, or a fasting glucose level of� 126 mg/
dL. Metabolic syndrome was defined as a disease combined with hypertension, hyperglycemia,
central obesity, and dyslipidemia based on the National Cholesterol Education Program
Expert Panel and Adult Treatment Panel III criteria. Chronic kidney disease (CKD) was
defined as a glomerular filtration rate (GFR) < 60 mL/min/1.73 m2, as estimated by the Modi-
fication of Diet in Renal Disease methods.
Aims
The purpose of this study was to determine the risk of CD and UC based on the presence of
anemia and hemoglobin levels to analyze whether anemia defined by WHO criteria could be
used as a marker for the detection of subclinical CD and UC.
Statistical analysis
Continuous variables were reported as mean ± standard deviation using Student’s t-test. Cate-
gorical variables were analyzed using the χ2 test. The incidence was determined as incidence
cases divided by the summation of follow-up period and multiplied by 105. Follow-up dura-
tions were expressed as person-years. Kaplan-Meier method was used to compare the cumula-
tive incidence probability of UC and CD based on the presence of anemia. The hazard ratio
(HR) of the risk for developing IBD was analyzed with 95% confidence intervals (CI) using the
Cox proportional hazard method. The adjusted HRs for age, sex, BMI, smoking, alcohol con-
sumption, physical activity, metabolic syndrome, income, and GFR were calculated. Subgroup
analysis was performed with respect to age, sex, CKD, overweight, and smoking. A P
value < 0.05 was considered as statistically significant. All statistical analyses were conducted
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using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) and SAS Version 9.3 (SAS Institute,
Cary, NC, USA).
Ethical considerations
The Institutional Review Board (IRB) of the Seoul National University Hospital approved the
study waived the need for informed consent as part of my study approval due to the non-inter-
ventional, retrospective design of the study (IRB Number, H-1703-107-840). All resident regis-
tration numbers were encrypted to protect personal privacy. All data used in this analysis was
completely anonymous and all personally identifiable information was removed. The public
health data could be obtained through the approval of Korea NHI data sharing service (NHIS-
2019-1-155).
Results
Baseline characteristics of study population
A total of 9,962,064 people who participated in the NHSP during the index year were included
in this study. Among them, 1,095,924 individuals (11%) had anemia according to WHO crite-
ria. The mean ages of anemic and non-anemic participants were 51.1 and 46.6 years, respec-
tively. Mean follow-up period was 7.3 ± 0.6 years. Compared to individuals without anemia,
those with anemia were significantly associated with old age, female gender, non-smokers,
non-drinkers, low physical activity, low BMI, low income, and urban residence (P-value for
each variable < 0.0001). The prevalence of hypertension and DM was significantly higher in
participants with anemia than in those without anemia (P-value for each variable < 0.0001).
By contrast, dyslipidemia and metabolic syndrome were significantly less common in the ane-
mic group than in the non-anemic group (P-value for each variable < 0.0001). Participants
with anemia showed significantly lower serum creatinine levels and GFR than those without
anemia (Table 1).
Risk of IBD in patients with anemia stratified with respect to the
hemoglobin level
We analyzed the incidence and HR of IBD in anemic and non-anemic groups. The incidence
(per 100,000 person-years) of CD in participants with anemia was higher than that in non-ane-
mic participants (2.89 vs 1.84; P < 0.0001). Model 1 was adjusted with respect to age and sex
in anemic and non-anemic groups, whereas model 2 was adjusted for age, sex, BMI, smoking,
alcohol consumption, physical activity, income, and GFR. The HR of CD was significantly
higher in the anemic group than the non-anemic group as analyzed using both models 1 and 2
(model 2; adjusted HR, 2.084; 95% CI, 1.769–2.455; P< 0.001; Table 2). The incidence (per
100,000 person-years) of UC in the anemic and non-anemic groups was 6.88 and 8.11, respec-
tively. The adjusted HR of UC did not significantly differ between anemic and non-anemic
groups (model 2, adjusted HR 0.972, 95% CI 0.880–1.073, P = 0.754). The cumulative inci-
dence probability of UC and CD was shown in Fig 1. The risk of CD was inversely propor-
tional to the patient hemoglobin level (Fig 2A). There were sex differences in the association
between hemoglobin level and the risk of developing CD, as males had stronger associations
than females (Fig 2B and 2C). By contrast, there was no significant association between the
hemoglobin level and the risk of developing UC (Fig 2D–2F).
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Anemia during follow-up and the risk of developing IBD
Among 6,696,826 individuals without anemia at the index date, 352,464 (5.3%) patients devel-
oped anemia at the two-year follow-up exam. The risk of developing CD was significantly
higher in anemic patients than in individuals without anemia in 2011 (adjusted HR 2.763, 95%
CI 2.254–3.387) (Table 3). The risk of developing CD was more prominent in male patients
with post-anemia than in female patients (adjusted HR, 4.311 vs. 2.178, respectively). By con-
trast, there was no significant difference in the risk of UC development based on the presence
Table 1. Baseline characteristics of the study population.
Anemia a
No. (%) No Yes P-value
No. of patients 8,866,140 1,095,924
Age, years b 46.64 ± 13.88 51.13 ± 15.22 < .0001
Male (%) 5,197,461 (58.6) 256,831 (23.4) < .0001
Height, cm b 164.51 ± 9.19 158.82 ± 7.78 < .0001
Body weight, kg b 64.69 ± 11.60 57.73 ± 9.37 < .0001
BMI, kg/m2 b 23.81 ± 3.20 22.86 ± 3.12 < .0001
< 18.5 (underweight) 312,457 (3.5) 65,809 (6.0)
18.5–23.0 (normal) 3,380,556 (38.1) 541,315(49.4)
23.0–25.0 (overweight) 2,224,838 (25.1) 242,013(22.1)
25.0–30.0 (obese I) 2,628,311 (29.7) 222,445(20.3)
> 30.0 (obese II) 319,978 (3.6) 24,342(2.2)
Waist circumference, cm b 80.63 ± 9.01 77.00 ± 8.90 < .0001
Residence; Urban (%) 4,078,434 (46.0) 507,467 (46.3) < .0001
Income (%) c 811,322 (10.28) 284,602 (13.77) < .0001
Smoking (%) < .0001
Nonsmoker 5,023,316 (56.7) 904,726 (82.6)
Former smoker 1,340,490 (15.1) 87,931 (8.0)
Current smoker 2,502,334(28.2) 103,267 (9.4)
Drinking (%) < .0001
None 4,357,263 (49.1) 775,320 (70.7)
Mild 3,855,113 (43.5) 291,507 (26.6)
Heavy 653,764 (7.4) 29,097 (2.7)
Exercise; Yes (%) 4,640,617 (52.3) 481,636 (44.0) < .0001
Underlying illness (%)
Hypertension 2,260,085 (25.5) 302,447 (27.6) < .0001
Dyslipidemia 1,632,304 (18.4) 187,974 (17.2) < .0001
Diabetes mellitus 755,131 (8.52) 112,363 (10.25) < .0001
Metabolic syndrome 820,865 (11.27) 273,136 (10.23) < .0001
Initial laboratory findings b
Hemoglobin, g/dL 14.29 ± 1.33 11.28 ± 0.99 < .0001
Creatinine, 1.02 ± 0.89 0.93 ± 0.75 < .0001
GFR 88.48 ± 45.14 87.10 ± 34.40 < .0001
BMI, body mass index; GFR, glomerular filtration ratio; No, number.
a Anemia is defined as a hemoglobin level less than 13 g/dL in males and 12g/dL in females according to WHO criteria.
b Mean ± standard deviation.
c Individuals with income less than 20% of total population were identified.
https://doi.org/10.1371/journal.pone.0238244.t001
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of post-anemia among non-anemic patients at baseline (adjusted HR 1.135, 95% CI 1.005–
1.282), regardless of sex.
Subgroup analysis
Subgroup analyses were performed according to age, sex, CKD, overweight, smoking behavior,
and alcohol consumption to assess the impact of anemia on the risk of developing IBD (Fig 3).
A J-curve relationship was observed between age and the risk of CD in anemic patients. By
contrast, anemic patients did not have a significantly increased risk of developing UC com-
pared to the non-anemic group, regardless of age. Male patients with anemia had a signifi-
cantly higher risk of CD development than female patients (adjusted HR, 1.432 vs. 1.240,
respectively; P = 0.0136). persons with anemia and BMI under 23 kg/m2 also had a higher risk
of CD than overweight patients (adjusted HR, 1.348 vs. 1.304, respectively; P = 0.0041). CKD,
smoking behavior, and alcohol consumption did not affect the risk of developing CD in
Table 2. Risk of inflammatory bowel disease according to the presence of anemia.
Anemia UC (No) Adjusted HR (95% CI) CD (No) Adjusted HR (95% CI)
Model 1 a Model 2 b Model 1 a Model 2 b
Yes 467 1.033 (0.936–1.140) 0.972 (0.880–1.073) 196 2.243 (1.904–2.641) 2.084 (1.769–2.455)
No 4,533 1 (Ref.) 1 (Ref.) 1,030 1 (Ref.) 1 (Ref.)
P-valve 0.0702 0.7594 < .0001 < .0001
CD, Crohn’s disease; CI, confidence intervals; HR, hazard ratios; No, number; Ref., reference; UC, ulcerative colitis.
a Model 1: Adjusted by age and sex.
b Model 2: Adjusted by age, sex, body mass index, smoking, alcohol consumption, exercise, metabolic syndrome, income, and glomerular filtration ratio.
https://doi.org/10.1371/journal.pone.0238244.t002
Fig 1. Cumulative incidence probability of ulcerative colitis and Crohn’s disease according to the presence of anemia.
https://doi.org/10.1371/journal.pone.0238244.g001
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anemic patients (Table 4). The risk of developing UC in anemic patients was similar to that in
the non-anemic group regardless of this variants. Alcohol consumption is known to increase
Fig 2. Risk of inflammatory bowel disease according to the hemoglobin levels (A, D) in total population, (B, E) male (C, F) female. CI, confidence interval; HR, hazard
ratio; Ref, reference.
https://doi.org/10.1371/journal.pone.0238244.g002



















HR (95% CI) b
UC No 2,891 8.91 1 (ref.) 2087 10.74 1 (ref.) 804 6.19 1 (ref.)






CD No 583 1.80 1 (ref.) 423 2.18 1 (ref.) 160 1.23 1 (ref.)






CD, Crohn’s disease; CI, confidence intervals; HR, hazard ratios; No, number; Ref., reference; UC, ulcerative colitis.
a Anemia during follow-up was defined as a case that became anemic in the 2-year follow-up exam among non-anemic individuals at baseline.
b HR was adjusted by age, sex, body mass index, smoking, alcohol consumption, exercise, metabolic syndrome, income, and glomerular filtration ratio.
https://doi.org/10.1371/journal.pone.0238244.t003
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iron uptake, and can possibly confound the association between anemia and development of
UC and CD. HR of CD was 2.038 (1.723–2.411) in anemic patients who did not drink alcohol
and 3.482 (1.686–7.191) in anemic patients who drank alcohol, which was not statistically sig-
nificant (P-value for interaction, 0.182). Therefore, the effect of anemia on CD development
was independent of alcohol consumption (S1 Table).
Fig 3. Hazard ratio of inflammatory bowel disease in patients with anemia according to age, sex, and body mass index. Error bars represent 95% CI. CI, confidence
interval.
https://doi.org/10.1371/journal.pone.0238244.g003
Table 4. Subgroup analysis of risk for inflammatory bowel diseases among anemic patients.
Subgroup UC HR (95%CI) CD HR (95%CI) P-value for Interaction (CD)
Age 20–29 0.982 (0.911,1.059) 1.628 (1.478,1.794) 0.0739
30–39 1.054 (0.996,1.117) 1.494 (1.362,1.639)
40–49 0.993 (0.947,1.040) 1.265 (1.144,1.397)
50–59 0.984 (0.936,1.035) 1.166 (1.038,1.309)
� 60 0.963 (0.911,1.018) 1.295 (1.155,1.451)
Sex Male 0.995 (0.965,1.025) 1.432 (1.353,1.515) 0.0136
Female 0.975 (0.935,1.017) 1.240 (1.148,1.340)
CKD No 0.992 (0.968,1.018) 1.329 (1.268,1.393) 0.5351
Yes 0.943 (0.853,1.043) 1.295 (1.099,1.526)
Overweight No 0.987 (0.953,1.022) 1.348 (1.269,1.433) 0.0041
Yes 0.993 (0.960,1.027) 1.304 (1.220,1.395)
Smoking No 0.993 (0.965,1.021) 1.309 (1.241,1.382) 0.383
Yes 0.971 (0.925,1.019) 1.383 (1.273,1.502)
Alcohol No 0.991 (0.966,1.016) 1.321 (1.261,1.385) 0.4965
Yes 0.957 (0.872,1.052) 1.411 (1.189,1.675)
CD, Crohn’s disease; CI, confidence intervals; CKD, chronic kidney disease; HR, hazard ratios; UC, ulcerative colitis.
https://doi.org/10.1371/journal.pone.0238244.t004
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Discussion
We investigated the incidence and risk of IBD in anemic patients using a large-scale, popula-
tion-based cohort of nearly 10 million Korean patients. The incidence and risk of CD were sig-
nificantly higher in the anemic group than the non-anemic group, but this association was not
observed for UC. The risk of CD development was correlated with the severity of anemia as
determined by the hemoglobin level. When patients were stratified with respect to hemoglobin
levels, the risk of CD was 3.3 times higher in the lowest 10% group than in the highest 10%
group. The presence of anemia within 2 years was associated with a 2.8-fold increased risk of
developing CD compared to the non-anemic group. To the best of our knowledge, this is the
first epidemiological study to demonstrate the association between anemia and the develop-
ment of IBD in the general population.
In a recent study, the median duration from the first IBD symptoms to diagnosis was 6.2
and 2.4 months in patients with CD and UC, respectively. However, 25% of the study popula-
tion had longer diagnosis time intervals of more than 21 and 6 months, respectively, from the
presentation of initial symptoms [18]. The diagnostic delay was associated with increased risk
of surgery related to IBD. Considering the time interval between the presentation of intestinal
inflammation and symptoms, it is imperative to have a good marker for early detection of IBD
to prevent disease-related complications and surgery. Our data indicate that anemia is a prom-
ising marker that predicts the presence of chronic intestinal inflammation, especially in CD
patients. Thus, patients with recently presented anemia are recommended for further evalua-
tion of the possibility of CD, particularly in light of the impact of newly developed anemia on
the risk of CD among individuals without baseline anemia in this study.
Anemia is one of the most common extra-intestinal manifestations related to IBD. Previous
studies reported the prevalence and risk factors for anemia in IBD. A large-scale cohort study
in the United States reported that the prevalence of anemia in IBD patients was up to 50.1% at
the time of diagnosis [19, 20]. An increased risk of anemia was associated with surgery for
IBD, high inflammatory marker levels such as C-reactive protein, high erythrocyte sedimenta-
tion rate, female sex, and use of biological or immunomodulator therapies [19]. In a European
population-based inception cohort study, anemia was more frequent in CD (49%) than in UC
(39%) during the first year after diagnosis, and extensive UC and colonic CD with penetrating
type were risk factors of anemia development [21]. Another population-based cohort study in
Sweden revealed that the extensive colitis of UC and stricturing phenotype of CD were signifi-
cantly associated with an increased risk of anemia [22]. Patients with IBD and anemia have a
poorer prognosis than IBD patients without anemia. Anemia can affect multiple factors in IBD
patients, including hospitalization, quality of life, surgical complications including poor out-
come, medical costs, and mortality [23–25]. These findings suggest that anemia may present
during the early stage of IBD, perhaps on a subclinical level, and may be strongly associated
with IBD disease severity and extent, eventually leading to poor clinical outcomes. Diagnostic
delays were more prominent for CD than UC, and anemia was more prevalent in CD than
UC. Our data suggest that the development of anemia is a marker for preclinical IBD. UC may
have fewer chances of developing anemia than CD due to the relatively short diagnostic delay
and low prevalence of anemia.
Anemia in IBD is caused primarily by iron deficiency or anemia of chronic diseases [22, 24,
26, 27]. Iron deficiency secondary to gastrointestinal blood loss or chronic inflammatory
mucosal damage can cause anemia in IBD. Severe anemia could be caused by chronic mucosal
inflammation or microscopic gastrointestinal bleeding that occurs before the diagnosis of IBD.
Chronic mucosal inflammation in IBD reduces iron absorption and leads to iron deficiency
[28]. Anemia in IBD also can be caused by anemia of chronic diseases with persistent
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inflammatory status in IBD. Malnutrition and malabsorption via inflamed gastrointestinal
tract could cause anemia. A recent study reported that subclinical inflammation may affect
iron status and hemoglobin concentrations [29]. However, it remains unclear whether the pre-
dictive role of anemia in the detection of CD differs according to the etiology of anemia.
We stratified patients with respect to age to evaluate age-specific risks of CD among anemic
patients. The results showed a unique J-shape curve between age and the risk of developing
CD. This curve is consistent with the results of a recent Korean population-based cohort study
of the incidence of CD with respect to age [30]. These data indicate that the age-specific inci-
dence rates of CD peaked in the teens and twenties, then decreased markedly, and subse-
quently peaked again in the 60s. A recent Swiss IBD cohort study also reported that pediatric-
onset CD was associated with higher rates of anemia compared to adult-onset CD [31]. Taken
together, the trends in the age-specific risk of developing CD among anemic patients indicate
that anemia is a good marker for early detection of CD in the general population.
The risks of developing CD were more prominent in men than in women in our study.
Men with the lowest 10% of hemoglobin levels had a 4.5-fold increased risk of CD compared
with the highest 10% group. Considering the high prevalence of anemia in premenopausal
women, the incidence of IBD in women is considered to be lower than that in men, which sug-
gests that the presence of anemia for early detection of CD is more critical in men in clinical
practice.
This population-based study has several limitations due to its retrospective cohort design.
First, we could not assess the etiology of anemia from the claims data. The impact of anemia
on IBD extent and severity could not be evaluated. A subsequent population-based study will
be required to determine the effects of anemia and anemia type on the development of IBD.
Second, there was a concern about immortal time bias because the hemoglobin levels are time-
varying covariates. In this retrospective study, serial results of hemoglobin levels within 2 years
in the study population were not available, and not all the subjects underwent the 2-year fol-
low-up screening exams. Because the Cox proportional hazard models were established in the
subpopulations who participated the 2-year follow-up screening exam among the non-anemic
individuals at baseline, time-dependent Cox proportional hazard models were not used for
controlling immortal time bias. It should be noted that the presence of anemia identified in a
single test at baseline and newly developed anemia at follow-up are useful markers for subclini-
cal CD, respectively.
In conclusion, patients with anemia, especially newly developed anemia, were associated
with an increased risk of developing CD, not UC. The risk of developing CD was inversely pro-
portional to the hemoglobin level, which was a marker for anemia severity. A J-curve relation-
ship was observed between age and the risk of developing CD among anemic patients, similar
to that observed for the incidence of CD based on age. Therefore, anemia should promote fur-
ther investigation for early detection of CD in general population, especially in males.
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